Patent Board Grants Inter Partes Review Of Cancer-Fighting Therapy

Mealey's (June 1, 2016, 1:32 PM EDT) -- ALEXANDRIA, Va. — A claimed method and composition for treating cancer with hormone therapy is likely unpatentable under 35 U.S. Code Section 103, the Patent Trial and Appeal Board ruled May 31 in a decision granting inter partes review (Amerigen Pharmaceuticals Ltd. v. Janssen Oncology Inc., No. IPR2016-00286, PTAB).

(Decision available. Document #16-160606-032Z.)

Respondent Janssen Oncology Inc.’s U.S. patent No. 8,822,438 describes administration of an effective amount of 17α-hydroxylase/C17, 20-lyase (CYP17) — an enzyme involved in testosterone synthesis — inhibitor, such as abiraterone acetate, with a...
To view the full article, register now.